Doctors Without Borders (MSF) has definitively rejected an Israeli order to hand over sensitive staff information, following months of failed negotiations. The move comes amid a wider crackdown on aid groups and a devastating toll on healthcare workers in the conflict.
Industrial equipment maker Graco (NYSE: GGG) is expanding its powder technology footprint through the acquisition of Color Service, a specialist in gravimetric dosing. The move coincides with the company reporting record quarterly sales, fueled by organic growth and strategic integrations, signaling a period of focused expansion for the Minnesota-based firm.
United Rentals reported strong Q4 results, driven by data center and power sector demand, and issued 2026 guidance forecasting continued revenue growth. Management highlighted a robust project pipeline while navigating margin pressures.
Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.
While Alpha IVF Group Berhad's latest earnings disappointed the market, a deeper look reveals a significant accrual ratio, raising questions about the quality of its profits and the sustainability of its cash generation.
A Connecticut man faces charges after police say he operated a snow plow under the influence of cocaine, leading to a destructive path through residential properties on his very first shift.
French authorities have demanded 1.7 billion euros from Uber for unpaid payroll taxes, alleging the ride-hailing giant misclassified drivers as independent contractors to avoid employer obligations, a report reveals.
Finnish cargo handling giant Kalmar Oyj partners with Tata Consultancy Services to build an AI-powered digital core, aiming to boost operational efficiency and solidify its long-term service offerings in the global ports sector.
Egypt reopened the Rafah border crossing on Tuesday, allowing the first medical evacuation from Gaza since its latest closure. A critically wounded Palestinian patient was transferred to an Egyptian hospital, amid ongoing hostilities in the Strip.
A Foxboro woman's two-year struggle with a defective high-end oven underscores the enduring power of state consumer protection laws, even after a manufacturer's warranty expires.
While October's COLA announcement brings temporary relief, a growing body of evidence suggests the formula used to calculate Social Security adjustments fails to reflect the real-world expenses of retirees, creating a persistent and compounding budget gap.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Shares of clinical-stage biotech Scholar Rock (NASDAQ: SRRK) have surged nearly 60% in three months, closing at $44.34. This rally, backed by promising clinical progress, has investors weighing its premium valuation against its long-term potential in treating serious diseases.
As economic pressures mount, flexible remote work opportunities are evolving. We examine four proven side gigs that experts project can still generate significant weekly earnings from home in the coming years.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Congress faces a critical vote to avert a prolonged shutdown, while newly released documents shed light on the Minneapolis shooting involving immigration officers and the Epstein case continues to reverberate.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Analysts maintain a bullish outlook on Goodyear Tire & Rubber, citing strong potential in the replacement tire market and favorable inventory trends, with a median price target suggesting a 7% upside.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
